Literature DB >> 24470512

Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps.

Carla Guarinos1, Miriam Juárez, Cecilia Egoavil, María Rodríguez-Soler, Lucía Pérez-Carbonell, Ramón Salas, Joaquín Cubiella, Francisco Rodríguez-Moranta, Luisa de-Castro, Luis Bujanda, Anna Serradesanferm, David Nicolás-Pérez, Maite Herráiz, Fernando Fernández-Bañares, Alberto Herreros-de-Tejada, Elena Aguirre, Judith Balmaña, María-Luisa Rincón, Angeles Pizarro, Francisco Polo-Ortiz, Adela Castillejo, Cristina Alenda, Artemio Payá, José-Luis Soto, Rodrigo Jover.   

Abstract

PURPOSE: The present study aimed to determine the prevalence of MUTYH mutations in patients with multiple colonic polyps and to explore the best strategy for diagnosing MUTYH-associated polyposis (MAP) in these patients. EXPERIMENTAL
DESIGN: This study included 405 patients with at least 10 colonic polyps each. All cases were genetically tested for the three most frequent MUTYH mutations. Whole-gene analysis was performed in heterozygous patients and in 216 patients lacking the three most frequent mutations. Polyps from 56 patients were analyzed for the KRAS-Gly12Cys and BRAF V600E somatic mutations.
RESULTS: Twenty-seven (6.7%) patients were diagnosed with MAP, of which 40.8% showed serrated polyps. The sensitivity of studying only the three common variants was 74.1%. Of 216 patients without any monoallelic mutation in common variants, whole-gene analysis revealed biallelic pathogenic mutation in only one. G396D mutation was associated with serrated lesions and older age at diagnosis. There was a strong association between germinal MUTYH mutation and KRAS Gly12Cys somatic mutation in polyps. BRAF V600E mutation was found in 74% of serrated polyps in MUTYH-negative patients and in none of the polyps of MAP patients.
CONCLUSIONS: We observed a low frequency of MUTYH mutations among patients with multiple adenomatous and serrated polyps. The MAP phenotype frequently included patients with serrated polyps, especially when G396D mutation was involved. Our results show that somatic molecular markers of polyps can be useful in identifying MAP cases and support the need for the complete MUTYH gene analysis only in patients heterozygous for recurrent variants. ©2014 AACR

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24470512     DOI: 10.1158/1078-0432.CCR-13-1490

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

Review 1.  Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management.

Authors:  Priyanka Kanth; Jade Grimmett; Marjan Champine; Randall Burt; N Jewel Samadder
Journal:  Am J Gastroenterol       Date:  2017-08-08       Impact factor: 10.864

2.  Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.

Authors:  Matthew B Yurgelun; Matthew H Kulke; Charles S Fuchs; Brian A Allen; Hajime Uno; Jason L Hornick; Chinedu I Ukaegbu; Lauren K Brais; Philip G McNamara; Robert J Mayer; Deborah Schrag; Jeffrey A Meyerhardt; Kimmie Ng; John Kidd; Nanda Singh; Anne-Renee Hartman; Richard J Wenstrup; Sapna Syngal
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

Review 3.  [Hereditary colorectal cancer : An update on genetics and entities in terms of differential diagnosis].

Authors:  T T Rau; H Dawson; A Hartmann; J Rüschoff
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

4.  Establishing a diagnostic road map for MUTYH-associated polyposis.

Authors:  Ester Borras; Melissa W Taggart; Patrick M Lynch; Eduardo Vilar
Journal:  Clin Cancer Res       Date:  2014-01-31       Impact factor: 12.531

5.  TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Authors:  V Cervera-Carrascon; M Siurala; J M Santos; R Havunen; S Tähtinen; P Karell; S Sorsa; A Kanerva; A Hemminki
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

Review 6.  Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis.

Authors:  Brandie Heald; Heather Hampel; James Church; Beth Dudley; Michael J Hall; Maureen E Mork; Aparajita Singh; Elena Stoffel; Jessica Stoll; Y Nancy You; Matthew B Yurgelun; Sonia S Kupfer
Journal:  Fam Cancer       Date:  2020-07       Impact factor: 2.375

Review 7.  Advances in Hereditary Colorectal and Pancreatic Cancers.

Authors:  Meghan L Underhill; Katharine A Germansky; Matthew B Yurgelun
Journal:  Clin Ther       Date:  2016-04-02       Impact factor: 3.393

Review 8.  Hereditary or Not? Understanding Serrated Polyposis Syndrome.

Authors:  Peter P Stanich; Rachel Pearlman
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 9.  The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management.

Authors:  Maria Liz Leoz; Sabela Carballal; Leticia Moreira; Teresa Ocaña; Francesc Balaguer
Journal:  Appl Clin Genet       Date:  2015-04-16

10.  Clinical guideline seom: hereditary colorectal cancer.

Authors:  C Guillén-Ponce; R Serrano; A B Sánchez-Heras; A Teulé; I Chirivella; T Martín; E Martínez; R Morales; L Robles
Journal:  Clin Transl Oncol       Date:  2015-11-19       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.